News – beLAB1407

beLAB1407 TO DEVELOP NOVEL APPROACH FOR CARDIOVASCULAR DISEASES

Hamburg, Germany, 24 June 2024:

The beLAB1407 BRIDGE partnership translates therapeutic innovations from leading academic institutions in the UK
University of Bristol receives award to develop a novel antisense-based approach for atherosclerosis

Evotec SE today announced that the University of Bristol has been granted an award within the framework of the beLAB1407 BRIDGE partnership to develop a novel antisense oligonucleotide (“ASO”) based treatment for atherosclerosis, the leading cause of cardiovascular diseases.

beLAB1407, one of Evotec’s global portfolio of BRIDGE partnerships, was launched in 2021 by Evotec and collaborating partners to identify and advance novel and breakthrough drug discovery opportunities across multiple therapeutic areas. In 2023 beLAB1407 expanded to include the University of Bristol, the University of Glasgow, and Queen Mary University of London, leveraging Evotec’s multimodality platform to validate
innovative drug discovery concepts.

EVOTEC EXPANDS beLAB1407 BRIDGE PARTNERSHIP WITH BRISTOL MYERS SQUIBB TO INCLUDE 3 NEW UNIVERSITY PARTNERS

Hamburg, Germany, 22 November 2023:

beLAB1407 WAS CREATED BY EVOTEC AND BRISTOL MYERS SQUIBB TO TRANSLATE INNOVATIONS FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
EVOTEC’S UNIQUE MULTIMODALITY PLATFORM WILL NOW BE MADE AVAILABLE TO THE UNIVERSITY OF BRISTOL, UNIVERSITY OF GLASGOW AND QUEEN MARY UNIVERSITY OF LONDON TO VALIDATE FIRST-IN-CLASS CONCEPTS

Evotec SE today announced the expansion of its $20 million beLAB1407 BRIDGE partnership with Bristol Myers Squibb to include the Universities of Bristol and Glasgow as well as Queen Mary University of London.

beLAB1407 was launched in 2021 with the Universities of Birmingham, Dundee, Edinburgh and Nottingham as founding partners to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas. Under the expanded beLAB1407 agreement, the Universities of Bristol and Glasgow as well as Queen Mary University of London will benefit from access to funding, expertise and drug discovery and development platforms spanning multiple disease areas and modalities.

ACCESS BELAB1407 AND BELAB2122 WORLD LEADING DRUG DISCOVERY PLATFORMS

Hamburg, Germany, 22 February 2023:

To help our academic partners realise their drug discovery ideas, beLAB1407 offers preferred access to Evotec´s world leading drug discovery platforms and expertise.

From HTS to preclinical drug development, from small molecules to gene therapy, we provide you with all the necessary expertise and experimentation to develop your ideas to the clinic.

Starting in March 2023, in a series of tailor presentations, beLAB1407 would like to invite all our partners to join a special series of 1 hour webinars highlighting some of the key technologies that are available to you via the funding scheme.

From Evotec specialists you will be guided through diverse topics with the opportunity to explore how beLAB1407 can support your drug discovery needs.

Over the course of 2023, the following topics will be presented by Evotec´s experts:

Hit identification capabilities including HTS and virtual screening
Generation and optimisation of human antibodies
Medicinal chemistry optimisation of early-stage hits
RNA and DNA targeting
Drugging the undruggable, anti-sense oligonucleotides and protein degraders

This is a great opportunity to hear how beLAB1407 can support you in your ambitions to develop tomorrow´s drugs. We look forward to welcoming you!

EVOTEC’S TRANSLATIONAL BRIDGE beLAB1407 AWARDS PROJECT FROM DUNDEE UNIVERSITY

Hamburg, Germany, 1 August 2022:

PROJECT ORIGINATES FROM DR IGNACIO MORAGA’S LAB AND FOCUSES ON INFLAMMATORY DISORDERS
BELAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC, BRISTOL MYERS SQUIBB AND UK UNIVERSITIES

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb, aiming to accelerate translational research from the UK’s academic life science ecosystem.

EVOTEC ANNOUNCES FIRST FUNDED PROJECTS OF TRANSLATIONAL BRIDGE beLAB1407 IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 27 October 2021:

FIRST TWO PROJECTS FROM THE UNIVERSITIES OF BIRMINGHAM AND EDINBURGH SELECTED
beLAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first two projects to be developed within beLAB1407, a collaboration between Evotec and Bristol Myers Squibb to accelerate translational research from the UK’s academic life science ecosystem. Only six months after signing the beLAB1407 collaboration agreement in May 2021, the first projects to be developed within this academic BRIDGE collaboration have now been identified.

EVOTEC LAUNCHES “beLAB1407” TO ACCELERATE TRANSLATIONAL RESEARCH FROM THE UK’S ACADEMIC LIFE SCIENCE ECOSYSTEM IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 06 May 2021:

beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
THE COLLABORATION LEVERAGES EVOTEC’S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.

EVOTEC LAUNCHES “beLAB1407” TO ACCELERATE TRANSLATIONAL RESEARCH FROM THE UK’S ACADEMIC LIFE SCIENCE ECOSYSTEM IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 06 May 2021:

beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
THE COLLABORATION LEVERAGES EVOTEC’S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR